Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 3
2016 1
2021 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Minimal residual disease in multiple myeloma: bringing the bench to the bedside.
Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M, Landgren O. Mailankody S, et al. Nat Rev Clin Oncol. 2015 May;12(5):286-95. doi: 10.1038/nrclinonc.2014.239. Epub 2015 Jan 27. Nat Rev Clin Oncol. 2015. PMID: 25622976 Free PMC article. Review.
Many patients are now achieving a complete response to treatment, and consequently highly sensitive assays are needed for detection of minimal residual disease (MRD) in patients with MM. Results of multicolour flow cytometry and deep-sequencing …
Many patients are now achieving a complete response to treatment, and consequently highly sensitive assays are needed for detection of mi …
Participation in the College of American Pathologists Laboratory Accreditation Program Decreases Variability in B-Lymphoblastic Leukemia and Plasma Cell Myeloma Flow Cytometric Minimal Residual Disease Testing: A Follow-up Survey.
Hupp MM, Bashleben C, Cardinali JL, Dorfman DM, Karlon W, Keeney M, Leith C, Long T, Murphy CE, Pillai V, Rosado FN, Seegmiller AC, Linden MA. Hupp MM, et al. Arch Pathol Lab Med. 2021 Mar 1;145(3):336-342. doi: 10.5858/arpa.2019-0493-CP. Arch Pathol Lab Med. 2021. PMID: 32886757 Free article.
CONTEXT.-: Minimal residual disease (MRD) testing by flow cytometry is ubiquitous in hematolymphoid neoplasm monitoring, especially B-lymphoblastic leukemia (B-ALL), for which it provides predictive information and guides managemen …
CONTEXT.-: Minimal residual disease (MRD) testing by flow cytometry is ubiquitous in hematolymphoi …
Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, Monreal M, de Tute R, Vergilio JA, Rawstron AC, Paiva B. Arroz M, et al. Cytometry B Clin Cytom. 2016 Jan;90(1):31-9. doi: 10.1002/cyto.b.21228. Epub 2015 Jun 2. Cytometry B Clin Cytom. 2016. PMID: 25619868 Free article.
BACKGROUND: Major heterogeneity between laboratories in flow cytometry (FC) minimal residual disease (MRD) testing in multiple myeloma (MM) must be overcome. Cytometry societies such as the International …
BACKGROUND: Major heterogeneity between laboratories in flow cytometry (FC) minimal residual di …
Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program.
Keeney M, Halley JG, Rhoads DD, Ansari MQ, Kussick SJ, Karlon WJ, Mehta KU, Dorfman DM, Linden MA. Keeney M, et al. Arch Pathol Lab Med. 2015 Oct;139(10):1276-80. doi: 10.5858/arpa.2014-0543-CP. Epub 2015 Feb 19. Arch Pathol Lab Med. 2015. PMID: 25695342 Free article.
CONTEXT: Flow cytometry is often applied to minimal residual disease (MRD) testing in hematolymphoid neoplasia. ...OBJECTIVES: To broadly survey flow cytometry laboratories about MRD testing in laboratories, if perfor …
CONTEXT: Flow cytometry is often applied to minimal residual disease (MRD) testing in hematolympho …